Details of the Drug Reposition

General Information of This Drug (ID: DMPZ97S)

Drug Name
Trofinetide   DMPZ97S
Synonyms Glypromate analogs (oral, neuroprotection), Neuren; NNZ-2566 (oral, neurodegeneration/injury); NNZ-2566 (oral, neurodegeneration/injury), Neuren
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Rett syndrome DISGG5UV LD90.4 Approved [1]
------------------------------------------------------------------------------------
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Type-1 diabetes DIS7HLUB 5A10 Phase 2 [2]
Fragile X syndrome DISE8W3A LD55 Phase 2 [3]
Traumatic brain injury DISN8K9H NA07.Z Phase 2 [4]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217026.
2 NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)